MOTS-c

What it is

MOTS-c is a short peptide made of 16 amino acids that is encoded within the mitochondrial open reading frame of the 12S ribosomal RNA, which makes it one of a small family of mitochondrial-derived peptides S4S5. It was first described as a metabolic regulator that activates AMP-activated protein kinase (AMPK), a central cellular energy sensor, and that influences glucose handling in muscle cells in laboratory models S3S5. Researchers have also observed that the body's own circulating and muscle levels of MOTS-c rise in response to exercise, which is part of why it is discussed as an exercise-linked signaling molecule S5. It is a research compound, not an approved medicine S2.

Marketed as

In gray-market and wellness settings MOTS-c is often promoted with claims that it acts as an exercise mimetic, boosts metabolism and fat loss, improves insulin sensitivity, and supports healthy aging and physical performance S4S5. These are marketing claims and framing, not established clinical effects; the underlying human evidence needed to confirm such benefits does not yet exist in controlled form S4S5. This page describes how the peptide is marketed only to give context, and does not endorse or validate those claims.

Regulatory status (US)

MOTS-c is not approved by the US Food and Drug Administration for any use S2. It does not appear on the FDA list of bulk drug substances that may be used in compounding under section 503A, and the agency has treated substances carrying significant safety risks as candidates for enforcement rather than routine compounding S2. Because it is unapproved, MOTS-c circulates largely as a research chemical and gray-market product rather than as a lawfully marketed drug or dietary supplement S2. US policy on compounded peptides is under active federal review, so its status should be re-checked over time S2.

Around the world

MOTS-c is not an approved therapeutic product in the major regulated markets, and its scientific interest to date has come from academic and preclinical research rather than from regulatory approvals anywhere S4S5. The most consequential international rule that applies to it is the anti-doping framework maintained by the World Anti-Doping Agency, whose Prohibited List is adopted globally across regulated sport S1.

Evidence

The foundational research on MOTS-c comes from animal and cell studies, in which the peptide activated AMPK, affected glucose transport, and reduced markers of obesity and insulin resistance in mice S3. Later reviews describe preclinical findings such as protection against diet-related metabolic dysfunction and improved physical capacity in aged mice S4S5. In humans the data remain preliminary and largely observational: for example, lower circulating MOTS-c has been associated with poorer metabolic control, but association is not the same as a demonstrated treatment effect S5. An early human study evaluating MOTS-c for insulin sensitivity has been registered, reflecting genuine but still unproven clinical interest S6. Overall the evidence base is best described as preclinical with early human interest S4S5S6.

Anti-doping

MOTS-c is prohibited in sport. The World Anti-Doping Agency explicitly names it on the 2026 Prohibited List within the metabolic modulators category, listed among activators of AMP-activated protein kinase (AMPK) S1. Substances in this class are prohibited at all times, meaning both in-competition and out-of-competition, so any athlete subject to anti-doping rules should treat MOTS-c as a banned substance S1.

Safety

Because MOTS-c has not been through the approval process, there is no established human safety profile, no regulated manufacturing standard, and no approved labeling to rely on S2. Gray-market material also carries the general risks of unapproved injectables, including uncertain purity, identity, and sterility, since these products are not subject to the quality controls applied to approved drugs S2. Anyone weighing legitimacy should recognize that an unapproved, non-standardized research peptide sits outside the safeguards of the regulated drug system S2.

What's changing

The near-term developments to watch are on two fronts. First, human research is beginning to move beyond observation: a registered trial is now evaluating MOTS-c for insulin sensitivity, which over time may produce the controlled data that the field currently lacks S6. Second, US regulatory posture toward compounded peptides is under active review, and MOTS-c's compounding eligibility and enforcement treatment could shift as that process plays out S2. Its anti-doping status, by contrast, is already settled: it is named on the current WADA Prohibited List S1.